BackStealth BioTherapeutics Overview

Stealth BioTherapeutics Total Current Liabilities

Track Stealth BioTherapeutics's total current liabilities ($9.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$9.89M
↓ 38.98% YoYΔ $-6.32M vs prior year quarter

Peer trimmed avg / median

Loading

Stealth BioTherapeutics Total Current Liabilities History

Loading

Stealth BioTherapeutics vs. peers: Total Current Liabilities Comparison

Loading

Stealth BioTherapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Stealth BioTherapeutics (MITO) FAQ

Stealth BioTherapeutics (MITO) currently reports a total current liabilities of $9.9M as of March 2022. That compares with $16M in the prior-year period — down 39.0% year over year. Use the charts on this page to explore Stealth BioTherapeutics's total current liabilities history and peer comparisons.

Stealth BioTherapeutics's total current liabilities decreased from $16M to $9.9M — a 39.0% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Stealth BioTherapeutics reported $9.9M in total current liabilities as of March 2022. That compares with $16M in the prior-year period — down 39.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $9.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Stealth BioTherapeutics, and consider following MITO for alerts when major investors trade the stock.

Stealth BioTherapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $9.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MITO with unrelated industries.